InVivo Therapeutics (NVIV) Stock Price, News & Analysis

Company Overview

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.22 to $0.79
• 52-Week Range: N/A
• Volume: 1.89 million shs
• Average Volume: 8.25 million shs
• Market Capitalization: $997 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVIV Stock Analysis - Frequently Asked Questions

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) issued its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($61.75) earnings per share (EPS) for the quarter.

When did InVivo Therapeutics' stock split?

InVivo Therapeutics's stock reverse split on the morning of Wednesday, April 27th 2022.The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Tonix Pharmaceuticals (TNXP), Flexion Therapeutics (FLXN), OPKO Health (OPK), Acasti Pharma (ACST) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 5/13/2020
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NVIV
• CIK: 1292519
• Web: www.invivotherapeutics.com
• Phone: (617) 863-5500
• Fax: N/A
• Employees: 6
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -75.04%
• Return on Assets: -65.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.30
• Quick Ratio: 14.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.48 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,110,000
• Free Float: 3,029,000
• Market Cap: $997 thousand
• Optionable: Not Optionable
• Beta: 0.65